scholarly journals A novel immunocompetent model of metastatic prostate cancer‐induced bone pain

The Prostate ◽  
2020 ◽  
Vol 80 (10) ◽  
pp. 782-794
Author(s):  
Zhiqiang Liu ◽  
Stephen F. Murphy ◽  
Jian Huang ◽  
Lan Zhao ◽  
Christel C. Hall ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Pain ◽  
Metastatic Prostate Cancer

scholarly journals Characterization of a rat model of metastatic prostate cancer bone pain

2010 ◽  
pp. 213 ◽  
Author(s):  
Gurmit Singh ◽  
De Ciantis ◽  
Henry ◽  
Yashpal
Keyword(s):  
Prostate Cancer ◽  
Rat Model ◽  
Bone Pain ◽  
Metastatic Prostate Cancer

scholarly journals Metastatic prostate cancer presenting as tumour-induced osteomalacia

2019 ◽  
Vol 12 (7) ◽  
pp. e229434
Author(s):  
Awo Akosua K Layman ◽  
Shivam Joshi ◽  
Sanjeev Shah
Keyword(s):  
Prostate Cancer ◽  
Lower Extremity ◽  
Parotid Gland ◽  
Basal Cell ◽  
Paraneoplastic Syndrome ◽  
Bone Pain ◽  
Metastatic Prostate Cancer ◽  
Prostate Adenocarcinoma ◽  
Malignant Tumours ◽  
Oncogenic Osteomalacia

Tumour-induced osteomalacia (TIO), or oncogenic osteomalacia, is a paraneoplastic syndrome marked by hypophosphataemia, renal phosphate wasting, bone pain, weakness, and fractures. The syndrome has been reported with both benign and malignant tumours including parotid gland basal cell tumours, thyroid carcinomas, colon adenocarcinomas, and prostate cancer. Often, the syndrome is marked by an insidious course during which patients present with generalised bony pain and weakness, which do not resolve until the underlying tumour is identified and treated. We present a case of a patient with Parkinson’s disease whose subacute weakness, lower extremity paresis, and renal phosphate wasting led to the synchronous diagnosis of metastatic prostate adenocarcinoma and TIO.

Bisphosphonates Treatment in Metastatic Prostate Cancer

2005 ◽  
Vol 3 (2) ◽  
pp. 49-54
Author(s):  
F. Berardinelli ◽  
M. Iannucci ◽  
V. Verratti ◽  
W. Fusco ◽  
M. Nicolai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Pain ◽  
Metastatic Prostate Cancer ◽  
Common Site ◽  
The Third ◽  
Clinical Complications ◽  
Therapeutic Choice ◽  
Skeletal Related Events ◽  
Skeletal Integrity ◽  
Tumor Drugs

The skeleton is the third most common site for cancer to spread after the liver and lungs. Malignancies that can cause destruction of skeletal bones include multiple myeloma and metastatic diseases of the lung, prostate and other solid cancers. The clinical complications include pain, fractures, compression of the spinal cord and hypercalcemia of malignancy. Bisphosphonates are bone-seeking agents originally designed to treat loss of bone density. Accumulating data show that they are effective in diseases in which there is upregulation of osteoclastic or osteolytic activity. Bisphosphonates can reduce skeletal-related events and bone pain, as well as reduce the adverse effects of androgen deprivation therapy on skeletal integrity. However, it is clear that bisphosphonates do not represent a decisive treatment in the care of metastases but a therapeutic choice in synergy with regular anti-tumor drugs. The preclinical and clinical data to support this are reviewed here.

TREATMENT OF VITAMIN D DEFICIENCY IN PATIENTS WITH METASTATIC PROSTATE CANCER MAY IMPROVE BONE PAIN AND MUSCLE STRENGTH

2000 ◽  
Vol 163 (1) ◽  
pp. 187-190 ◽  
Author(s):  
PETER J. VAN VELDHUIZEN ◽  
SARAH A. TAYLOR ◽  
STEPHEN WILLIAMSON ◽  
BETTY M. DREES
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Muscle Strength ◽  
Vitamin D Deficiency ◽  
Bone Pain ◽  
Metastatic Prostate Cancer

Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate Cancer

2003 ◽  
Vol 21 (23) ◽  
pp. 4277-4284 ◽  
Author(s):  
Eric J. Small ◽  
Matthew R. Smith ◽  
John J. Seaman ◽  
Stephanie Petrone ◽  
Mildred Ortu Kowalski
Keyword(s):  
Prostate Cancer ◽  
Bone Resorption ◽  
Bone Pain ◽  
Metastatic Prostate Cancer ◽  
Specific Antigen ◽  
Double Blind ◽  
Treatment Benefit ◽  
Bone Resorption Markers ◽  
Pamidronate Disodium ◽  
Analgesic Use

Purpose: Bone metastases occur in approximately 80% of patients with advanced prostate cancer. Pain is common in these patients. The purpose of this study was to evaluate the effect of an intravenous bisphosphonate, pamidronate disodium, on pain control in metastatic prostate cancer patients. Patients and Methods: Two multicenter, double-blind, randomized, placebo-controlled trials were conducted in patients with bone pain due to metastatic prostate cancer, with disease progression after first-line hormonal therapy. Intravenous pamidronate disodium (90 mg) or placebo was administered every 3 weeks for 27 weeks. Efficacy was measured via self-reported pain score (Brief Pain Inventory), analgesic use, the proportion of patients with a skeletal-related event (SRE; defined as pathologic fracture, radiation or surgery to bone, spinal cord compression, or hypercalcemia), and a pilot quantitative measurement of mobility. Laboratory evaluations included serum prostate-specific antigen, interleukin-6, bone alkaline phosphatase, and urinary bone resorption markers. Results: Results of the two trials were pooled. There were no sustained significant differences between the pamidronate and placebo groups in self-reported pain measurements, analgesic use, proportion of patients with an SRE, or mobility at week 9 or 27. Urinary bone resorption markers were suppressed in the pamidronate group compared with placebo. Conclusion: Pamidronate disodium failed to demonstrate a significant overall treatment benefit compared with placebo in palliation of bone pain or reduction of SREs. Evaluation of more potent bisphosphonates in patients with prostate cancer is warranted.

Pain as an Indicator of Bone Metastasis

1988 ◽  
Vol 29 (4) ◽  
pp. 445-449 ◽  
Author(s):  
E. Palmer ◽  
B. Henrikson ◽  
K. McKusick ◽  
H. W. Strauss ◽  
F. Hochberg
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Bone Disease ◽  
Bone Pain ◽  
Metastatic Prostate Cancer ◽  
Metastatic Bone Disease ◽  
Common Finding ◽  
Breast Metastases ◽  
Skeletal Pain ◽  
Self Administered Questionnaire

Patients with breast or prostate cancer routinely referred for bone scintigraphy were evaluated for the presence of skeletal pain, as determined by a self administered questionnaire. Pain was a common finding, whether or not metastatic disease was present, and occurred in over half of patients. Although most patients with bone metastases did report bone pain, a significant fraction (21% of breast and 22% of prostate patients) were asymptomatic. A distinct minority of individual anatomic regions of metastasis were painful: pain was reported in 23 % of sites of breast metastases and 15% of metastatic prostate cancer sites. Of all sites at which pain was present, metastases were demonstrated in only about one half. These results indicate that pain is not a reliable indicator of the presence of location of metastatic bone disease.

Sign in / Sign up

Export Citation Format

Share Document